Clearmind Medicine Return on Equity (ROE) Growth & History (CMND)

Clearmind Medicine's return on equity was −179.39% for fiscal 2025.

View full Clearmind Medicine company overview

Clearmind Medicine annual return on equity history

Clearmind Medicine annual return on equity

Fiscal yearPeriod endedReturn on equityChange (percentage points)
20252025-10-31−179.39%+77.50 pp
20242024-10-31−256.89%
20222022-10-31−571.69%−426.43 pp
20212021-10-31−145.26%

Clearmind Medicine return on equity trends

Between the periods ended 2021-10-31 and 2025-10-31, Clearmind Medicine's return on equity decreased from −145.26% to −179.39%, a change of −34.13 percentage points. The latest reported quarter, Q2 2026, shows −20.76%.

About the metric

What return on equity (ROE) means

Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.

Calculation and source

How return on equity is calculated

TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Clearmind Medicine source filings ↗

Community posts

It’s quiet here.

No posts about CMND yet. Start the conversation.

Write the first post